Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials [0.03%]
新型胃肠胰神经内分泌肿瘤的[177Lu]Lu-Dotatate治疗的成本效益分析：基于NETTER-2试验结果的分析研究
Adrien Holzgreve,Lena M Unterrainer,Maximilian Tiling et al.
Adrien Holzgreve et al.
The recently published results of the NETTER-2 trial suggest the use of [177Lu]Lu-DOTATATE as a new standard of care in first-line therapy of patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tu...
161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas [0.03%]
针对CD30阳性淋巴瘤的放射免疫治疗161Tb治疗方法
Elisa Rioja-Blanco,Yara Banz,Christoph Schlapbach et al.
Elisa Rioja-Blanco et al.
Lymphoma remains a significant health concern, necessitating innovative treatment approaches. 161Tb's coemission of ultra-short-range conversion and Auger electrons, with its medium-energy β--particles, may enable the elimination of single...
Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View [0.03%]
采用长轴视野PET/CT扫描仪进行全身[18F]DPA-714动力学评估
Xavier Palard-Novello,Denise Visser,Maqsood Yaqub et al.
Xavier Palard-Novello et al.
Multisystemic inflammation might be a key pathophysiologic mechanism in post-coronavirus disease 2019 (post-COVID) syndrome. N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a] pyrimidin-3-yl)acetamide ([18F]DPA-714), which...
Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer [0.03%]
一种饮食诱导的肥胖乳腺癌模型中的颗粒酶B正电子发射断层扫描成像可预测免疫疗法的疗效
Shannon E Lynch,Corinne Crawford,Addison L Hunt et al.
Shannon E Lynch et al.
The effects of obesity on cancer treatment efficacy remain unclear, as both beneficial and detrimental modulations of the tumor immune microenvironment have been reported. We compared 68Ga-NOTA-GZP (βAla-Gly-Gly-Ile-Glu-Phe-Asp-CHO) PET im...
[18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease [0.03%]
[18F]FDG正电子发射断层扫描/X线计算机体层成像预测系统性硬化症相关间质性肺病患者的生存期
David M L Lilburn,Helen S Garthwaite,Balaji Ganeshan et al.
David M L Lilburn et al.
There are few effective prognostic biomarkers in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). We investigated the potential of [18F]FDG PET/CT to predict mortality in this population. Methods: In total, 4...
[18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study [0.03%]
18F-FDG代谢肿瘤体积在神经内分泌瘤中的预后价值：一项多中心研究
David L Chan,Aimee Hayes,Ioannis Karfis et al.
David L Chan et al.
[18F]FDG PET/CT avidity predicts higher-grade disease and worse prognosis in patients with metastatic neuroendocrine neoplasm. However, there is less evidence regarding the role of [18F]FDG-avid tumor volume in predicting prognosis. We plan...
Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience [0.03%]
177Lu-DOTATATE肽受体放射性核素治疗神经内分泌肿瘤骨转移患者的临床疗效：来自真实世界的经验体会
Kunal Ramesh Chandekar,Swayamjeet Satapathy,Sanjana Ballal et al.
Kunal Ramesh Chandekar et al.
Skeletal metastases portend a poor prognosis for patients with neuroendocrine tumors (NETs). Literature on peptide receptor radionuclide therapy (PRRT) specific to patients with skeletal metastases from NETs is scarce. This study assessed r...
Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice [0.03%]
临床实践中223 Ra治疗前列腺癌骨转移患者的影响因素及疗效分析
Joost H H M van Riel,Maarten L Donswijk,Christel Brouwer et al.
Joost H H M van Riel et al.
223Ra-dichloride (223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 223Ra injections, treatment may be repea...
Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors [0.03%]
建立神经内分泌肿瘤中177Lu-DOTATATE的体外剂量学模型和剂量效应关系
Giulia Tamborino,Pleun Engbers,Tijmen H de Wolf et al.
Giulia Tamborino et al.
This study investigates the radiobiology of peptide receptor radionuclide therapy (PRRT) using clinically relevant cancer cell lines by developing a framework for realistic cellular dosimetry in 2- and 3-dimensional cluster-forming configur...
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data [0.03%]
基于多中心数据的177Lu-DOTATATE肾脏吸收剂量能否通过预治疗SSTR-PET预测？
Azadeh Akhavanallaf,Zhonglin Lu,Avery B Peterson et al.
Azadeh Akhavanallaf et al.
Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to confirm sufficient tumor SSTR expression, but it also has potential to be used to personalize treatment by pre...